The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper.
Journal
Thrombosis and haemostasis
ISSN: 2567-689X
Titre abrégé: Thromb Haemost
Pays: Germany
ID NLM: 7608063
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
aheadofprint:
24
06
2021
pubmed:
26
6
2021
medline:
6
8
2021
entrez:
25
6
2021
Statut:
ppublish
Résumé
One year after the declaration of the coronavirus disease 2019 (COVID-19) pandemic by the World Health Organization (WHO) and despite the implementation of mandatory physical barriers and social distancing, humanity remains challenged by a long-lasting and devastating public health crisis. Non-pharmacological interventions (NPIs) are efficient mitigation strategies. The success of these NPIs is dependent on the approval and commitment of the population. The launch of a mass vaccination program in many countries in late December 2020 with mRNA vaccines, adenovirus-based vaccines, and inactivated virus vaccines has generated hope for the end of the pandemic. The continuous appearance of new pathogenic viral strains and the ability of vaccines to prevent infection and transmission raise important concerns as we try to achieve community immunity against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and its variants. The need of a second and even third generation of vaccines has already been acknowledged by the WHO and governments. There is a critical and urgent need for a balanced and integrated strategy for the management of the COVID-19 outbreaks organized on three axes: (1) The "PDA strategy" integrated into state policy for the support and expansion of health systems and introduction of digital organizations (i.e., telemedicine, e-Health, artificial intelligence, and machine-learning technology) is of major importance for the preservation of citizens' health and life world-wide.
Sections du résumé
BACKGROUND
One year after the declaration of the coronavirus disease 2019 (COVID-19) pandemic by the World Health Organization (WHO) and despite the implementation of mandatory physical barriers and social distancing, humanity remains challenged by a long-lasting and devastating public health crisis.
MANAGEMENT
Non-pharmacological interventions (NPIs) are efficient mitigation strategies. The success of these NPIs is dependent on the approval and commitment of the population. The launch of a mass vaccination program in many countries in late December 2020 with mRNA vaccines, adenovirus-based vaccines, and inactivated virus vaccines has generated hope for the end of the pandemic.
CURRENT ISSUES
The continuous appearance of new pathogenic viral strains and the ability of vaccines to prevent infection and transmission raise important concerns as we try to achieve community immunity against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and its variants. The need of a second and even third generation of vaccines has already been acknowledged by the WHO and governments.
PERSPECTIVES
There is a critical and urgent need for a balanced and integrated strategy for the management of the COVID-19 outbreaks organized on three axes: (1)
CONCLUSION
The "PDA strategy" integrated into state policy for the support and expansion of health systems and introduction of digital organizations (i.e., telemedicine, e-Health, artificial intelligence, and machine-learning technology) is of major importance for the preservation of citizens' health and life world-wide.
Identifiants
pubmed: 34169495
doi: 10.1055/a-1535-8807
pmc: PMC8322591
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
992-1007Investigateurs
Gregory Y H Lip
(GYH)
Michael Makris
(M)
Sam Schulman
(S)
Wolfgang Siess
(W)
Christian Weber
(C)
Informations de copyright
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Déclaration de conflit d'intérêts
None declared.
Références
Thromb Haemost. 2021 Jan;121(1):76-85
pubmed: 33378787
Thromb Haemost. 2021 Aug;121(8):982-991
pubmed: 33946120
N Engl J Med. 2021 Jun 10;384(23):2212-2218
pubmed: 33882219
Air Qual Atmos Health. 2020 Aug 3;:1-10
pubmed: 32837621
Cancer Discov. 2021 Feb;11(2):233-236
pubmed: 33355178
Virchows Arch. 2020 Sep;477(3):359-372
pubmed: 32642842
Eur J Intern Med. 2021 Jun;88:52-62
pubmed: 33820686
Thromb Haemost. 2020 Jul;120(7):1004-1024
pubmed: 32473596
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
Eur Respir Rev. 2021 Feb 9;30(159):
pubmed: 33568525
Thromb Haemost. 2020 Dec;120(12):1629-1641
pubmed: 33124029
Nature. 2020 Sep;585(7824):174-177
pubmed: 32901123
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355
pubmed: 32667669
Biomed Hub. 2020 Sep 17;5(3):1341-1363
pubmed: 33564668
Thromb Haemost. 2020 Dec;120(12):1680-1690
pubmed: 32961572
Am J Public Health. 2021 Mar;111(3):371-373
pubmed: 33566663
J Thromb Haemost. 2020 Sep;18(9):2110-2117
pubmed: 32608159
Am J Pathol. 2021 Jun;191(6):983-992
pubmed: 33741335
Nature. 2021 Jan;589(7843):500-501
pubmed: 33479534
Euro Surveill. 2020 Dec;25(49):
pubmed: 33303064
Thromb Haemost. 2021 Jul;121(7):849-853
pubmed: 33831961
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3
pubmed: 32369736
JMIR Med Inform. 2021 Feb 11;9(2):e24572
pubmed: 33534723
Int J Legal Med. 2020 Jul;134(4):1275-1284
pubmed: 32500199
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Nat Med. 2021 Feb;27(2):225-228
pubmed: 33082575
Res Pract Thromb Haemost. 2020 Jun 12;4(4):510-517
pubmed: 32542211
J Arrhythm. 2020 Dec 11;37(1):231-237
pubmed: 33664908
Histopathology. 2020 Aug;77(2):198-209
pubmed: 32364264
Am J Physiol Endocrinol Metab. 2020 Oct 1;319(4):E689-E708
pubmed: 32755302
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Am J Hematol. 2020 Jul;95(7):834-847
pubmed: 32282949
Nature. 2021 Jun;594(7862):259-264
pubmed: 33887749
Energy Res Soc Sci. 2020 Oct;68:101661
pubmed: 32839694
Emerg Infect Dis. 2021 May;27(5):1540-1543
pubmed: 33900195
Intern Emerg Med. 2021 Apr;16(3):803-804
pubmed: 33687691
J Adolesc Health. 2021 May;68(5):869-872
pubmed: 33824070
BMJ. 2021 Mar 9;372:n579
pubmed: 33687922
Thromb Haemost. 2020 Dec;120(12):1725-1732
pubmed: 32828072
Lancet. 2021 Feb 20;397(10275):671-681
pubmed: 33545094
Multidiscip Respir Med. 2021 Jan 18;16(1):748
pubmed: 33532070
Cerebrovasc Dis. 2021;50(3):326-331
pubmed: 33774618
Res Pract Thromb Haemost. 2021 Feb 24;5(2):296-300
pubmed: 33733028
Lancet Public Health. 2021 Apr;6(4):e222-e231
pubmed: 33556327
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
Lancet Public Health. 2020 May;5(5):e240
pubmed: 32247329
Nat Med. 2021 Jun 10;:
pubmed: 34113015
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Am J Public Health. 2021 Feb;111(2):205-208
pubmed: 33439703
Eur J Clin Invest. 2021 Apr;51(4):e13484
pubmed: 33400268
Healthcare (Basel). 2020 Dec 11;8(4):
pubmed: 33322316
BMC Infect Dis. 2021 Feb 10;21(1):169
pubmed: 33568097
Front Pharmacol. 2020 Sep 16;11:579886
pubmed: 33041824
Thromb Haemost. 2021 Jul;121(7):944-954
pubmed: 33677827
BMJ. 2021 May 5;373:n1114
pubmed: 33952445
Front Psychol. 2020 Nov 30;11:584500
pubmed: 33329241
J Thromb Haemost. 2020 Aug;18(8):2058-2060
pubmed: 32324960
Proc Natl Acad Sci U S A. 2021 Jun 22;118(25):
pubmed: 34099578
Sci Rep. 2021 Jun 2;11(1):11636
pubmed: 34079027
EClinicalMedicine. 2020 Dec;29:100639
pubmed: 33251499
Blood. 2021 May 14;:
pubmed: 33988688
Thromb Haemost. 2020 Dec;120(12):1691-1699
pubmed: 33186991
Glycobiology. 2020 Dec 9;30(12):981-988
pubmed: 32363391
Int J Mol Sci. 2021 Mar 17;22(6):
pubmed: 33802729
PLoS One. 2021 Jan 29;16(1):e0245656
pubmed: 33513157
JMIR Mhealth Uhealth. 2020 Jun 23;8(6):e19822
pubmed: 32516750
J Public Health (Oxf). 2021 Feb 09;:
pubmed: 33559682
Nature. 2021 Feb;590(7846):375-376
pubmed: 33547431
N Engl J Med. 2021 Jun 3;384(22):2092-2101
pubmed: 33835769
Nat Commun. 2021 Jan 15;12(1):378
pubmed: 33452267
Nutrients. 2021 Feb 26;13(3):
pubmed: 33652653
Nature. 2021 Feb;590(7846):382-384
pubmed: 33594289
Am Heart J. 2021 May;235:12-23
pubmed: 33577800
Thromb Haemost. 2020 Dec;120(12):1597-1628
pubmed: 32920811
Adv Rheumatol. 2020 Sep 22;60(1):50
pubmed: 32962761
Lancet. 2020 Jul 25;396(10246):219-221
pubmed: 32682489
JMIR Public Health Surveill. 2020 Apr 14;6(2):e18668
pubmed: 32250958
Spat Spatiotemporal Epidemiol. 2020 Aug;34:100355
pubmed: 32807400
Nature. 2021 Feb;590(7844):15-16
pubmed: 33514888
MMWR Morb Mortal Wkly Rep. 2021 Jun 11;70(23):846-850
pubmed: 34111060
N Engl J Med. 2021 Jun 3;384(22):2124-2130
pubmed: 33835768
Vaccines (Basel). 2021 Mar 11;9(3):
pubmed: 33799505
Chest. 2021 Mar;159(3):1182-1196
pubmed: 33217420
BMC Infect Dis. 2021 Feb 24;21(1):206
pubmed: 33627072
J Public Health Res. 2020 Dec 18;9(4):2011
pubmed: 33409247
Int J Infect Dis. 2021 Apr;105:307-311
pubmed: 33592338
Nature. 2021 May;593(7857):136-141
pubmed: 33706364
Nat Med. 2021 Feb;27(2):205-211
pubmed: 33469205
Front Immunol. 2021 Mar 19;12:654165
pubmed: 33815415
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Thromb Haemost. 2020 Nov;120(11):1590-1593
pubmed: 32679596
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
Eur Respir J. 2021 Jun 24;57(6):
pubmed: 33795319
JAMA Intern Med. 2021 Jul 1;181(7):997-1000
pubmed: 33818615
Res Pract Thromb Haemost. 2020 Sep 25;:
pubmed: 33043231